{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-052949","form_type":"8-K","ticker":null,"cik":"0001584751","company_name":"Talis Biomedical Corp","filed_at":"2024-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.088426+00:00","generated_at":"2026-06-02T23:09:41.401961+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Talis Biomedical extends waiver of registration rights with Baker Brothers through May 27, 2024","bullets":["Company and Baker Brothers entities agree to extend waiver of registration rights originally set for 30 days.","Waiver now runs through May 27, 2024, covering all registrable securities beneficially owned by the stockholders.","Extension follows termination of S-3 registration statement in March 2024 due to company no longer being eligible.","Waiver applies to Sections 2.1(a) and 2.1(b) of the Registration Rights Agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-052949","json":"https://secwatch.observer/filing/0000950170-24-052949.json","markdown":"https://secwatch.observer/filing/0000950170-24-052949.md","text":"https://secwatch.observer/filing/0000950170-24-052949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1584751/000095017024052949/0000950170-24-052949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1584751/000095017024052949/tlis-20240429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:09:41.401961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"526e15079ccd393c20cd1f39989a7007129204b3","claim":"Talis Biomedical Corp amended Amendment to the Waiver Agreement with Baker Brothers Life Sciences L.P. and 667, L.P. valued at Extension of registration rights waiver through May 27, 2024 (effective 2024-04-29).","evidence_excerpt":"On April 29, 2024, The Baker Funds agreed to extend this waiver through May 27, 2024 (the “Amendment to the Waiver Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1584751/000095017024052949/0000950170-24-052949-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Baker Brothers Life Sciences L.P. and 667, L.P."},{"label":"Value","value":"Extension of registration rights waiver through May 27, 2024"},{"label":"Effective","value":"2024-04-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}